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Abstract Aims/hypothesis: Fibrinogen and elevated AER
increase cardiovascular mortality, but few data are avail-
able in the type 2 diabetic population. We have conducted
an 11-year follow-up study of the Casale Monferrato co-
hort to assess: (1) the long-term predictive role of AER
independently of conventional risk factors; (2) the shape
of its relationship with cardiovascular mortality; and (3)
whether fibrinogen has a predictive effect independent of
the increased cardiovascular risk associated with nephropa-
thy. Methods: During the follow-up period (1991–2001)
a population-based cohort of 1,565 patients was regular-
ly examined, and measurements of HbA1c were central-
ised. Multivariate Cox proportional hazards modelling
was employed to assess the role of fibrinogen and AER
as predictors of all-cause and cardiovascular mortality, in-
dependently of baseline variables and individual cumula-
tive average values of HbA1c during follow-up. Results: In
10,890.2 person-years of observations, 685 deaths were iden-
tified, giving an all-cause mortality rate of 63.4 per 1,000
person-years (95% CI 58.8–68.3). In Cox regression ana-
lyses, the strongest predictor of cardiovascular mortality
was macroalbuminuria (relative risk 2.18, 95% CI 1.62–
2.94), which was mainly associated with a high risk of short-
term mortality. No increased risk was evident until the upper
microalbuminuric range of AER values. Plasma fibrinogen
was also a major independent predictor, and its role was not
modified by AER, or by the exclusion of subjects developing
chronic renal failure or diabetic nephropathy during follow-
up. Conclusions/interpretation: The results indicate that: (1)
AER is the main independent predictor of 11-year cardio-
vascular mortality; (2) this effect is mainly evident in the
upper range of microalbuminuria and in macroalbuminuria;
and (3) fibrinogen has an independent effect on cardiovas-
vascular mortality, but no synergistic effect with AER, sug-
gesting that both endothelial dysfunction and chronic inflam-
mation are involved in the excess cardiovascular mortality of
type 2 diabetic patients.
Keywords Diabetic nephropathy . Fibrinogen . Mortality .
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Introduction
Albuminuria and fibrinogen are considered to be cardio-
vascular risk factors in both non-diabetic [1–4] and diabetic
subjects [5–7]. Moreover, cross-sectional studies have pro-
vided evidence that fibrinogen levels are independently
associated with AER in both type 1 and type 2 diabetic
subjects [8–10]; however, the pathophysiological rela-
tionship between these two factors and the clinical rele-
vance of their combined effect on cardiovascular risk
remain unknown. Recent prospective data from the Casale
Monferrato Study have provided evidence that hyperfibrin-
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ogenaemia independently predicts progression to overt
diabetic nephropathy in type 2 diabetes [11]. Since cardio-
vascular mortality is higher in subjects with diabetic ne-
phropathy than in subjects with diabetes alone [12–23], it is
clinically relevant to assess whether the role of fibrinogen
as a predictor of cardiovascular mortality is independent
of baseline AER and progression to overt diabetic neph-
ropathy. Albuminuria is considered to be a marker of endo-
thelial cell damage, whereas fibrinogen is an indicator of
chronic inflammation, which has been implicated in the
pathogenesis of atherosclerosis and unstable atherosclero-
tic plaque in the coronary arteries. Therefore, the clinical
usefulness of fibrinogen in the assessment of cardiovascu-
lar risk in diabetic patients would be increased if evidence
were found that fibrinogen has a role that is independent
of that of AER.
As regards albuminuria, its role as a cardiovascular risk
factor in type 2 diabetic subjects has been highlighted in a
systematic literature review [12] and in more recent studies
[13–24]. However, the interpretation of the results from
these studies has been hampered by: (1) the recruitment of
clinic-based rather than population-based cohorts of sub-
jects, which limits the extrapolation of the results to the
whole diabetic population; (2) the small number of analysed
events, which limits the power of the study for identifying
risk factors and their interactions; and (3) the narrow spec-
trum of risk factors examined, which limits the assessment
of inter-relationships between explanatory variables. More-
over, a number of critical questions have not been clarified
as yet. Firstly, whether the shape of the relationship between
AER and cardiovascular mortality is continuous or discrete.
Only the Heart Outcomes Prevention Evaluation (HOPE)
and the Prevention of Renal and Vascular End-Stage Dis-
ease (PREVEND) studies have previously examined this
issue, reporting an increasing trend in cardiovascular risk
even below the cut-off value for microalbuminuria, though
this was assessed according to albumin: creatinine ratios
and urinary albumin concentrations in these studies [13,
21]. Secondly, the role of AER as a predictor of long-term
mortality in diabetic subjects has not been conclusively
determined. Its role as a predictor of short-term mortality
has only been suggested by studies based on few person-
years of observations [24].
In this 11-year follow-up of the CasaleMonferrato cohort
of type 2 diabetic subjects we aimed to assess: (1) the long-
term predictive role of AER, independently of conventional
risk factors; (2) the shape of the relationship between AER
and cardiovascular mortality; and (3) whether the predic-
tive effect of fibrinogen is independent of the cardiovas-
cular risk associated with nephropathy.
Subjects and methods
The study population consisted of 1,565 patients with
known type 2 diabetes who were residents of the town of
Casale Monferrato in the north-west of Italy (93,477 in-
habitants) in 1988. Subjects were invited to attend a base-
line examination in 1991–1992 to assess the prevalence of
microalbuminuria, macroalbuminuria and cardiovascular
risk factors, and were followed up through December 2001
[25, 26]. They were identified using the following sources
of ascertainment: (1) diabetes clinic; (2) general practition-
ers; (3) hospital discharges; (4) prescriptions; and (5) sale
records of reagent strips and syringes. Patients cared for
exclusively by their general practitioners comprised 23.8%
of the cohort [27]. A high estimated completeness of as-
certainment (80%) was calculated by applying log-linear
models to the capture–recapture methods, which take into
account dependencies between data sources and hetero-
geneities of patients within sources [27]. Surveys conducted
within Italy showed that the subjects were representative of
Italian diabetic patients as regards age, sex, duration of
diabetes, BMI and type of antidiabetic treatment.
As described in detail elsewhere, all patients were in-
terviewed and examined by trained investigators at base-
line after having provided informed consent [25]. The
study was approved by the local ethics committee and was
performed in accordance with the Declaration of Helsinki.
Hypertension was defined as a systolic blood pressure
≥140 mmHg and/or a diastolic blood pressure ≥90 mmHg
and/or treatment with antihypertensive drugs. Venous blood
samples were collected in the fasting state for the deter-
mination of triglycerides, total cholesterol, HDL choles-
terol (enzymatic–colorimetric method, after precipitation
with Mn2+), HbA1c (Daiichi HPLC; Menarini, Florence,
Italy; laboratory reference range 3.8–5.5%) and fibrinogen
(Clauss method) [10]. LDL cholesterol was calculated
using Friedewald’s formula. All laboratory determinations
were centralised. AER was calculated on the basis of uri-
nary albumin concentration measured in a single timed
overnight urine collection by the nephelometric method
(Behring Nephelometer Analyzer; Behring Institute, Mar-
burg, Germany), after having excluded urinary tract in-
fection, congestive heart failure or other known causes of
non-diabetic renal diseases. Microalbuminuria and macro-
albuminuria were defined as an AER 20–200 μg/min and
an AER >200 μg/min, respectively. Smoking habit was
classified into one of three categories: never smoker, ex-
smoker (if the patient had stopped smoking at least 1 month
prior to the visit) and smoker. For all patients enrolled, the
date of diagnosis was retrieved and recorded. CHD was
defined by ECG abnormalities according to the Minnesota
code, as previously described [26].
During the follow-up period (1991–2001), patients were
regularly examined (three to four times per year) either at
the diabetes clinic or by general practitioners. As this pro-
spective study was designed to determine the incidence of
diabetic nephropathy and chronic renal failure [11, 28],
HbA1c, plasma creatinine and AER were regularly mea-
sured according to physician-scheduled plans at the main
hospital in the area. This allowed us to retrospectively ac-
cess a computerised database that included these centralised
measurements. Individual average values for HbA1c, which
were updated at each follow-up examination, were cal-
culated (cumulative individual averages).
The relevant time scale for the analysis was the time since
diabetes diagnosis to death or to 31 December 2001. In-
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formation on deaths and the causes of death was obtained
from the demographic files of towns of residence, hospital
discharges and autopsy records. Only one patient was lost to
follow-up. Underlying causes of death were derived and
coded by two authors according to the ninth revision of the
International Classification of Diseases (ICD). Diabetes
was coded as the underlying cause of death in only 63 cases.
Mortality rates were calculated by dividing the number of
deaths that occurred during the study period by the number
of person-years of observation.
Statistical analysis All continuous variables were cate-
gorised into quartiles of their distribution, apart from AER,
which was categorised into normoalbuminuria, microalbu-
minuria and macroalbuminuria and into deciles, and age,
which was categorised into 5-year age groups (<60, 60–64,
65–69, 70–74, 75–79, >79). Analyses were performed
using baseline variables. HbA1c values were measured at
baseline and during follow-up, and were included in models
using their cumulative individual average as a time-de-
pendent variable. In all tables, age- and sex-adjusted rel-
ative risks (RRs) are shown. Estimations of p values for
trend were calculated using the Mantel–Haenszel method.
The roles of AER and fibrinogen as predictors of cardio-
vascular and all-cause mortality, independently of conven-
tional risk factors, were assessed with multivariate Cox
proportional hazards models. Given the definition of the
time scale, all models were also adjusted for known du-
ration of diabetes. Variables included in the models fulfilled
the proportional hazard assumptions, since the results of
tests based on Schoenfeld residuals were not significant
[29], apart from borderline significance (p=0.06) for AER
categories. The likelihood ratio test was used to assess the
significance of variables. We tested for linear trend across
categorical variables by entering a single ordinal term into
the Cox regression model. In addition, we tested for de-
viation from linearity by comparing models containing
AER values categorised into deciles with those containing a
linear term in a likelihood ratio test with eight degrees of
freedom.
In order to evaluate the combined effect of AER and
fibrinogen on cardiovascular mortality, we divided the
cohort into 12 groups according to normoalbuminuria, mi-
croalbuminuria and macroalbuminuria and quartiles of fi-
brinogen. In these analyses, Cox regression was used to
simultaneously assess the risk of cardiovascular mortality in
each of the 12 groups, with normoalbuminuria and the
lowest quartile of fibrinogen as the reference group. The
hypothesis that fibrinogen and AER have an interactive
effect was tested in a Cox regression model that included a
term for the multiplicative interaction of AER (across the
three categories of normoalbuminuria, microalbuminuria
andmacroalbuminuria) and fibrinogen (across its quartiles).
The p value was two-sided, and a p value of less than
0.05 was considered to indicate statistical significance. All
analyses were performed using the STATA Statistical Soft-
ware Package, Release 8.0 (STATA, College Station, TX,
USA).
Results
At the baseline examination, the diabetic subjects had a
mean (±SD) age and diabetes duration of 68.9±10.7 and
10.8±7.0 years, respectively. As described previously [25],
the prevalences of hypertension, microalbuminuria and
macroalbuminuria were 84.5, 31.9 and 17.8%, respectively.
Patients cared for exclusively by their general practitioners
comprised 23.7% of the cohort. Frequencies of treatment
with diet, oral hypoglycaemic drugs and insulin were 12.2,
70.9 and 16.9%, respectively.
During the 11-year follow-up period, 685 deaths were
identified in 10,890.2 person-years of observations. This is
equivalent to an all-cause mortality rate of 63.4 per 1,000
person-years (95% CI 58.8–68.3). Cardiovascular mor-
tality (ICD 390–459) accounted for 49.8% (341/685) of
deaths (mortality rate 31.5 per 1,000 person-years, 95% CI
28.4–35.1). Women had significantly lower age-adjusted
mortality rates than men (RR=0.68, 95% CI 0.58–0.80 for
all-cause mortality; and RR=0.75, 95% CI 0.60–0.94 for
cardiovascular mortality).
Table 1 shows the age- and sex-adjusted relative risks for
all-cause and cardiovascular mortality in the cohort. In-
creasing trends of risks were evident across AER categories
and quartiles of fibrinogen and HbA1c cumulative average
values. The risks were higher in smokers, in subjects with
CHD, and in those cared for exclusively by their general
practitioners. Cardiovascular risks were higher in patients
with LDL : HDL cholesterol ratio values in the upper
quartiles and in hypertensive subjects, though they did not
reach statistical significance in the latter.
Predictors of cardiovascular and all-cause mortality In a
multiple-risk-adjusted model including conventional car-
diovascular risk factors (age, sex, hypertension, smoking
and LDL : HDL cholesterol ratio) and HbA1c cumulative
risk, microalbuminuria was the strongest independent pre-
dictor of cardiovascular mortality (RR=2.18, 95% CI 1.62–
2.94), whereas microalbuminuria was associated with a
relative risk of 1.08 (95% CI 0.82–1.45). A further ad-
justment for CHD only slightly modified the relative risks
(1.14 in microalbuminuric subjects and 2.08 in macro-
albuminuric subjects). Fibrinogen was also one of the main
independent predictors of cardiovascular mortality: the
relative risks were 1.41 (95% CI 0.98–2.04), 1.55 (95% CI
1.08–2.22), 1.63 (95% CI 1.15–2.31) in the lowest to the
highest quartiles, respectively. Compared with patients
cared for exclusively by general practitioners, patients cared
for by diabetologists had a 29 and a 33% lower risk of all-
cause and cardiovascular mortality, respectively, indepen-
dently of other risk factors (RR=0.81, 95% CI 0.67–0.98;
and RR=0.67, 95% CI 0.51–0.87, respectively). Further
adjustment for antidiabetic treatment, antihypertensive
treatments and triglycerides did not add significantly to
the models.
When deciles of AER values were included in models,
only high AER values were associated with increased risks
(Table 2). A tendency towards a U-shaped curve, with
large confidence intervals of point estimates, was evident,
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with the lowest all-cause mortality risk in subjects with an
AER between 11.68 and 15.00 μg/min. Borderline sig-
nificant deviations from linearity in relative risks for
cardiovascular mortality were found by comparing nested
models with decile indicators with those containing a lin-
ear term (likelihood ratio chi square statistic [LR], [df 8]=
15.90, p=0.0438) and by comparing a model with AER as
a continuous variable with a model that also included a
quadratic term (LR [df 1]=3.76, p=0.0525).
The independent effect of macroalbuminuria on cardio-
vascular mortality diminished with length of attained time
of follow-up (RR=2.98, 95% CI 0.95–9.41 for length <1.5
years; and RR=1.53, 95% CI 0.78–3.04 for length >6.0
years). Indeed, 53 of the 168 (31%) deaths that occurred
Table 1 All-cause and cardiovascular mortality rates in the population-based cohort of type 2 diabetes in the Casale Monferrato Study
according to selected variables at baseline examination (1991–1992)
All-cause mortality RRa (95% CI) Cardiovascular mortality RRa (95% CI)
Number of deaths Rate per 1,000
person-years
Number of deaths Rate per 1,000
person-years
AER
Normoalbuminuria 263 45.8 1.00 130 22.6 1.00
Microalbuminuria 227 67.9 1.41 (1.18–1.68) 95 28.4 1.18 (0.90–1.54)
Macroalbuminuria 168 118.0 2.29 (1.88–2.79) 99 69.2 2.73 (2.10–3.57)
p value for trendb <0.0001 <0.0001
Fibrinogen (g/l)
<3.00 135 48.4 1.00 58 20.8 1.00
3.00–3.49 143 53.7 1.14 (0.90–1.44) 73 27.4 1.37 (0.97–1.94)
3.50–4.10 183 68.2 1.46 (1.17–1.83) 86 32.1 1.58 (1.13–2.21)
>4.10 191 76.1 1.48 (1.18–1.85) 101 40.2 1.77 (1.28–2.46)
p value for trendb 0.0001 0.0002
HbA1c cumulative average (%)
<6.4 142 52.7 1.00 64 23.7 1.00
6.4–7.7 167 62.5 1.21 (0.96–1.51) 69 25.8 1.09 (0.78–1.54)
7.8–9.6 186 69.4 1.51 (1.21–1.89) 105 39.2 1.92 (1.40–2.63)
>9.6 155 60.1 1.49 (1.18–1.88) 78 30.2 1.66 (1.18–2.33)
p value for trendb <0.0001 <0.0001
LDL : HDL cholesterol ratio
<1.98 175 66.9 1.00 70 26.8 1.00
1.98–2.56 143 54.9 0.84 (0.67–1.05) 76 29.1 1.12 (0.81–1.56)
2.57–3.34 163 61.8 1.03 (0.83–1.28) 84 31.8 1.37 (1.00–1.88)
>3.34 155 60.5 1.15 (0.92–1.43) 85 33.1 1.60 (1.16–2.20)
p value for trendb 0.10 0.002
Hypertension
No 91 52.9 1.00 37 21.5 1.00
Yes 582 64.3 1.07 (0.85–1.34) 295 32.6 1.30 (0.92–1.83)
p value 0.47 0.09
Smoking
Never 419 60.5 1.00 213 30.8 1.00
Ex 147 69.1 1.40 (1.10–1.77) 71 33.4 1.49 (1.06–2.10)
Current 87 57.4 1.52 (1.16–1.98) 38 25.6 1.49 (1.01–2.20)
p value for trendb 0.002 0.052
CHD
No 408 59.1 1.00 204 29.6 1.00
Yes 168 79.4 1.25 (1.04–1.50) 19 42.1 1.33 (1.03–1.71)
p value 0.021 0.045
Physician
General practitioners 180 79.5 1.00 101 44.6 1.00
Diabetologists 502 59.3 0.87 (0.73–1.04) 238 28.1 0.76 (0.60–0.96)
p value 0.16 0.028
aAdjusted for age and sex (given the definition of the time period, relative risks were also adjusted for duration of diabetes)
bBased on the Mantel–Haenszel test for trend
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among macroalbuminuric patients occurred early (attained
time of follow-up <1.50 years), and most of those who died
did so within 6 years of follow-up (145/168, 86%). The
corresponding values were 15 and 73% among micro-
albuminuric subjects, and 16 and 70% among normoalbu-
minuric subjects.
Effect of fibrinogen and AER Since subjects with chronic
renal failure experience a higher rate of cardiovascular
mortality than those without this complication, we per-
formed analyses after excluding subjects who developed
chronic renal failure (n=72), defined as a creatinine value
>177 μmol/l, during the 11-year follow-up period [28]. In
this analysis, whereas the strength of other explanatory
variables did not change markedly, the role of fibrinogen
as an independent predictor became similar to that of
macroalbuminuria (RR=1.84, 95% CI 1.23–2.76 in the
upper quartile of fibrinogen; and RR=1.80, 95% CI 1.26–
2.58 in macroalbuminuric subjects). After further exclu-
sion of subjects with CHD at baseline, the relative risk
increased up to 1.97 in the upper quartile of fibrinogen
(95% CI 1.16–3.35), and decreased to 1.75 (95% CI 1.07–
2.85) in macroalbuminuric subjects.
The same analyses were repeated after excluding sub-
jects who were macrolbuminuric at baseline (n=268) and
those who progressed to macroalbuminuria during the 6
years of follow-up (n=202) [11]. In this analysis, the rela-
tive risk in the upper quartile of fibrinogen was 1.98 (95%
CI 1.13–3.37), whereas microalbuminuria was associated
with a relative risk of 0.91 (95% CI 0.61–1.37). When
analyses were performed in the 371 normoalbuminuric
subjects who remained normoalbuminuric at the sixth year
of follow-up (30 deaths), the relative risks across quartiles
of fibrinogen were (in ascending order): 1.22 (95% CI
0.37–4.02), 2.42 (95% CI 0.74–7.93) and 0.91 (95% CI
0.26–3.26) respectively.
In order to assess possible effect modification by fibri-
nogen on the AER predictivity of cardiovascular mortality,
an analysis was performed in strata defined by the AER
categories and fibrinogen quartiles combined. The results
of Cox regression analyses (Table 3) show an independent
effect of fibrinogen and AER categories on cardiovascular
mortality, with the highest risk in macroalbuminuric sub-
jects with fibrinogen levels >3.00 g/l, but no evidence for
an effect modification. Indeed, the expected relative ra-
tios obtained by the multiplication of the relative ratios in
each category of fibrinogen and AER are higher than the
observed relative ratios. No significant interactions were
found between AER categories and fibrinogen quartiles
(p=0.31).
Discussion
The results of the present analyses of the results of the
population-based Casale Monferrato Study indicate that
AER and fibrinogen are major predictors of cardiovascular
mortality risk in type 2 diabetic subjects. These effects were
independent of age, sex, duration of diabetes, blood pres-
sure, lipids, smoking and glycaemic control during the
study period, and were also independent of each other. No
increased risk of cardiovascular mortality was evident
within the normoalbuminuric range of AER values. The
role of baseline fibrinogen as a predictor of cardiovascular
mortality was not modified by AER, or by the exclusion of
Table 2 Relative risks of all-cause and cardiovascular mortality in
the Casale Monferrato cohort of type 2 diabetes according to AER
deciles
AER deciles
(μg/min)
All-cause
mortality
Cardiovascular
mortality
RRa (95% CI) RRa (95% CI)
<7.06 1.00 1.00
7.06–9.09 0.97 (0.65–1.43) 0.82 (0.46–1.46)
9.10–11.67 0.91 (0.61–1.37) 0.89 (0.51–1.55)
11.68–15.00 0.66 (0.43–1.01) 0.67 (0.37–1.21)
15.01–19.57 1.02 (0.69–1.51) 0.87 (0.50–1.51)
19.58–26.66 0.97 (0.65–1.45) 0.62 (0.33–1.15)
26.67–49.58 1.26 (0.86–1.85) 1.07 (0.62–1.83)
49.59–143.28 1.39 (0.96–2.02) 0.96 (0.55–1.66)
143.29–766.84 1.81 (1.25–2.62) 1.67 (0.99–2.79)
>766.84 1.71 (1.18–2.48) 1.78 (1.06–2.97)
p value for trend <0.001 <0.001
aAdjusted for age, sex, fibrinogen, HbA1c cumulative average, re-
ferring physician, LDL : HDL cholesterol ratio, hypertension and
smoking
Table 3 Modification effect of fibrinogen and AER on cardiovascular mortality in the Casale Monferrato cohort of type 2 diabetes
RRa (95% CI)
Fibrinogen <3.00 g/l Fibrinogen 3.00–3.49 g/l Fibrinogen 3.50–4.10 g/1 Fibrinogen >4.10 g/l
Normoalbuminuria 1 1.40 (0.76–2.58) 2.07 (1.17–3.66) 1.69 (0.93–3.08)
Microalbuminuria 1.71b 2.53b 2.06b
1.22 (0.58–2.56) 1.61 (0.84–3.07) 1.88 (0.96–3.69) 2.29 (1.24–4.25)
Macroalbuminuria 3.50b 5.17b 4.22b
2.50 (1.26–4.96) 3.34 (1.48–7.54) 3.05 (1.47–6.33) 3.82 (2.01–7.28)
aAdjusted for age, sex, HbA1c cumulative average, LDL : HDL cholesterol ratio, referring physician, hypertension, smoking and CHD
bExpected relative risks based on the assumption of a multiplicative model of effect modification
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subjects who developed chronic renal failure or macro-
albuminuria during follow-up. These findings are original;
no previous study has had the statistical power to assess the
inter-relationships between AER, fibrinogen and cardio-
vascular mortality. Furthermore, they are consistent with
the current hypothesis that endothelial dysfunction and
chronic inflammation are both involved in the excess car-
diovascular risk associated with type 2 diabetes [30]. It has
been suggested that the hyperglycaemia-induced formation
of reactive oxygen species in mitochondria and the gen-
eration of AGE might be the link between endothelial cell
damage and damage to glomerular cells, leading to albu-
minuria [30]. Fibrinogen has been found to predict prog-
ression of nephropathy [8–10], probably as a marker of
renal vascular damage; however, its role in diabetic subjects
could be even more complex than that of an indicator of
atherothrombotic disease. Indeed, emerging evidence sug-
gests that chronic inflammation may represent a component
of the metabolic syndrome, as it has been associated with
insulin resistance and cardiovascular risk factors in diabetic
subjects [31, 32].
Although fibrinogen has previously been reported to
predict cardiovascular mortality in the general population
[1–4], no data are available on its predictive role in the
diabetic population, apart from a Swedish study that in-
cluded 321 men with diabetes [5]. In a clinic-based cohort
of 363 Danish diabetic subjects, an excess risk of all-cause
mortality was reported to be associated with increased
inflammation-sensitive plasma proteins (fibrinogen, α1-
antitrypsin, haptoglobin, ceruloplasmin and orosomucoid)
[6]. Previous reports from the Casale Monferrato Study
have shown that hyperfibrinogenaemia is common in type
2 diabetes and is independently associated with higher AER
values [10]. Moreover, baseline fibrinogen levels predict
progression to macroalbuminuria, independently of blood
pressure, HbA1c cumulative average levels and plasma
lipids, suggesting that hyperfibrinogenaemia precedes overt
diabetic nephropathy [11]. Whether or not the role of fib-
rinogen as a predictor of cardiovascular mortality is due to
the increased cardiovascular risk associated with nephro-
pathy has not previously been established. The present
study is the first large population-based study on type 2
diabetes that has had the power to assess the predictive role
of fibrinogen and its inter-relationships with classical risk
factors and AER. Our results indicate that the predictive
effect of fibrinogen is strong and independent of both clas-
sical risk factors and AER progression. Indeed, even after
excluding patients who developed chronic renal failure or
those who progressed to macroalbuminuria during follow-
up, the predictive role of fibrinogen did not change. When
analyses were performed in normoalbuminuric subjects
whowere still normoalbuminuric at the sixth year of follow-
up, subjects in the second and the third quartiles of fib-
rinogen had higher relative risks than those in the lowest
quartile, although the point estimates had large confidence
intervals. The decrease in the point estimate of relative risk
in the upper quartile is probably due to chance, as the
analysis was based on only 30 deaths. Both AER and fib-
rinogen increased cardiovascular mortality, but we found no
synergy between them in our analyses. Fibrinogen is con-
sidered to be an indicator of inflammation, which is now
widely accepted as a contributory factor in the development
of atherosclerosis. Alternatively, fibrinogen may be directly
involved in atherosclerosis and thrombosis, since hyperfi-
brinogenaemia leads to enhanced coagulant activity and is
associated with increased blood viscosity [33]. Our findings
suggest that in diabetic subjects, this relatively inexpensive
test may be useful in the identification of high-risk subjects.
In diabetic subjects with plasma fibrinogen levels >4.1 g/l
and macroalbuminuria, the risk of cardiovascular mortality
is almost four times higher than that in normoalbuminuric
subjects with plasma fibrinogen levels <3.0 g/l. Lifestyle
modifications [34] and drugs, such as bezafibrate [33], have
been found to reduce fibrinogen levels, though not se-
lectively, which prevents assessment of the effect of its
reduction in intervention trials.
Endothelial dysfunction has been suggested as a link
between increased AER and cardiovascular events in type
2 diabetes [30]. Our findings indicate that the association
between AER and mortality is mainly evident in the
upper range of microalbuminuria and in macroalbumin-
uria (RR=1.35 and RR=2.04 for all-cause mortality; and
RR=1.08 and RR=2.18 for cardiovascular mortality, re-
spectively), with no increased risk evident in normoalbu-
minuria. These results are at variance with the HOPE
study, which found a continuously increasing risk in dia-
betic subjects even below the upper cut-off value for nor-
moalbuminuria [13]. However, it should be noted that the
Casale Monferrato cohort mainly included elderly sub-
jects (representative of the Italian diabetic population) who
were characterised by better glycaemic control and a later
age at diagnosis than those recruited in studies performed
in northern European countries and in the USA [26]. Fur-
thermore, diabetic patients recruited in the HOPE study had
at least one other cardiovascular risk factor, which in-
creased the expected number of cardiovascular events du-
ring follow-up.
Although lower than previously reported from mainly
clinic-based studies, our finding that microalbuminuria is
associated with a 30% increase in all-cause mortality, even
in the elderly, is relevant, highlighting the need for its pri-
mary prevention.
The Casale Monferrato Study recruited a prevalence
cohort of patients at baseline (i.e. a heterogeneous cohort as
regards duration of the disease and stage of its complica-
tions), and we found that an increase in the severity of
the baseline risk factors (such as macroalbuminuria) was
associated with an increase in short-term mortality. Indeed,
among macroalbuminuric subjects, 31% of deaths occurred
by the 1.5-year follow-up and 86% of deaths occurred by
the 6-year follow-up, compared with corresponding figures
of 15 and 73% among microalbuminuric subjects and 16
and 70% among normoalbuminuric subjects.
The strengths of the present study are the prospective
study design, the large population-based sample, and the
long survival follow-up. The Casale Monferrato Study re-
cruited a population-based cohort of subjects, allowing
subjects cared for exclusively by general practitioners to
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be compared with those cared for by diabetes clinics. In a
previous analysis of this cohort we found that patients with
more severe diabetes were selectively referred to the clin-
ics [26]. In spite of this, we found that patients cared for by
the diabetic clinics had a 33% lower risk of cardiovascular
mortality. This finding is consistent with the results of a
previous Italian study [35]. In Italy, all citizens are covered
by the national health system; thus, the choice of care is
not associated with socio-economic factors. However, our
finding should be interpreted with caution, since it could
be attributable to, among other factors, the different self-
referral patterns of patients.
In conclusion, this study demonstrates that, in type 2
diabetic subjects: (1) AER is the main independent pre-
dictor of 11-year mortality; (2) this effect is mainly evident
in the upper range of microalbuminuric values and in
macroalbuminuria; and (3) fibrinogen has an independent
effect on cardiovascular mortality, but has no synergistic
effect with AER. Therefore, both endothelial dysfunction
and chronic inflammation are likely to be involved in the
excess cardiovascular mortality in type 2 diabetic subjects.
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